Finanzen von Charming Medical Ltd (MCTA)MCTACharming Medical Ltd

Evaluating the bottom line, Charming Medical Ltd maintains a gross margin of 95.20%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.18%, while the net margin is -0.47%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MCTA converts its operational activities into shareholder value.

In the context of the broader market, MCTA competes directly with industry leaders such as ARTV and NAGE. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, MCTA's gross margin of 95.20% stands against ARTV's N/A and NAGE's 64.84%. Such benchmarking helps identify whether Charming Medical Ltd is trading at a premium or discount relative to its financial performance.

Charming Medical Ltd has shown strong financial performance with a gross margin of 95.77% in Q4 2025 and a net margin of 19.27% in the same period, indicating effective cost management and profitability.